Tuesday, November 25, 2014 10:35:27 PM
Based on recent PR they hired agency that will do work of uplisting before Oct'15. I have feeling that once Lympro is commercialized they will have enough cash on hand + Royalty payments and based on cash position they should be able to uplist and attract more investors that will help advance new drugs in the pipeline.
I'm not in favor of uplisting or spin-off because in both cases you get fractional shares and if you invested because you like specific product of company, you will get fractional shares after spinoff.
It all depends on how much they will get from Lympro and how much money they will need to advance ESS and Eltoprazine. Both have ODD so it might be cheaper. But If I have enough cash to advance them then I would not do uplisting or spinoff. There are lot of companies trading > $1 in OTC so I don't think it will affect SP because fundamental valuation of company doesn't change regardless of which exchange it is trading.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM